KREHER NERISSA 4

4 · Xeris Biopharma Holdings, Inc. · Filed Jul 2, 2026

AI-generated summary of this filing

Updated Jul 2, 2026

Xeris Biopharma (XERS) Director Nerissa Kreher Receives RSUs & Options

What Happened

Nerissa Kreher, a director of Xeris Biopharma (ticker: XERS), was granted equity on 2026-07-01: 33,582 restricted stock units (RSUs) at $0.00 and 37,910 stock options with an $8.00 exercise price (reported value $303,280). These grants are awards/compensation rather than open‑market purchases or sales.

Key Details

Transaction date: 2026-07-01; Form 4 filed 2026-07-02 (filed promptly the next day).
RSUs: 33,582 units, reported acquisition value $0.00 (F1). Each RSU converts to one share upon vesting.
Options: 37,910 stock options with $8.00 exercise price, reported value $303,280 (F2).
Vesting: Both the RSUs and options vest in equal annual installments over three years, contingent on continued service on the Board.
Shares owned after transaction: Not disclosed in this filing.
Filing status: Not marked late; appears timely (filed the business day after the report date).
Remark in filing: Director (board compensation).

Context

These grants are typical director compensation (awards), which are routine and do not by themselves signal a buy or sell intent. The options are not exercised or sold here; they are grants that will only convert to an ownership stake if vested and (for options) exercised later.

Form 4

Period: 2026-07-01

Director

Transactions

Award
Common Stock
[F1]
2026-07-01+33,582→ 33,582 total
Award
Stock Option (Right to Buy)
[F2]
2026-07-01$8.00/sh+37,910$303,280→ 37,910 total
Exercise: $8.00Exp: 2036-07-01→ Common Stock (37,910 underlying)

Footnotes (2)

[F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
[F2]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.

Signature

/s/ Beth Hecht, Attorney-in-Fact|2026-07-02

1 file